The online version of this article (doi:10.1186/1475-2840-11-27) contains supplementary material, which is available to authorized users.
Dr. Sjöholm has received research grants, and provided lectures, consultancies and expert testimony to several pharmaceutical companies involved in diabetes care, such as GlaxoSmithKline, Takeda Pharmaceuticals North America, Schering-Plough, Novo-Nordisk, Eli Lilly, Novartis, Aventis, Sanofi-Synthelabo, Bristol-Myers, Squibb, Merck Sharp & Dohme, Pfizer, Boehringer-Ingelheim, Selena-Fournier, Roche Diagnostics, Astra-Zeneca, Bayer, Pharmacia, and Hässle Pharmaceuticals.
Dr. Sjöholm is also on the National and/or European Advisory Boards in Diabetes Care for Eli Lilly, Takeda Pharmaceuticals, Novartis, Sanofi-Aventis, Merck Sharp & Dohme, Boehringer-Ingelheim and Astra-Zeneca.
LE and ÖE performed the experimental procedures, performed the statistical calculations, and contributed to results interpretation and discussion. TN, QZ and ÅS provided expertise in diabetes and endothelial dysfunction, the in vitro model, and conceived, designed and co-ordinated the research plan, respectively. LE, QZ and ÅS wrote the manuscript. LE, TN, QZ and ÅS contributed to discussion and edited the paper prior to submission. All authors read and approved the final manuscript.
The leading cause of death for patients suffering from diabetes is macrovascular disease. Endothelial dysfunction is often observed in type 2 diabetic patients and it is considered to be an important early event in the pathogenesis of atherogenesis and cardiovascular disease. Many drugs are clinically applied to treat diabetic patients. However, little is known whether these agents directly interfere with endothelial cell proliferation and apoptosis. This study therefore aimed to investigate how anti-diabetic and cardioprotective agents affect human coronary artery endothelial cells (HCAECs).
The effect of anti-diabetic and cardioprotective agents on HCAEC viability, proliferation and apoptosis was studied. Viability was assessed using Trypan blue exclusion; proliferation in 5 mM and 11 mM of glucose was analyzed using [3H]thymidine incorporation. Lipoapoptosis of the cells was investigated by determining caspase-3 activity and the subsequent DNA fragmentation after incubation with the free fatty acid palmitate, mimicking diabetic lipotoxicity.
Our data show that insulin, metformin, BLX-1002, and rosuvastatin improved HCAEC viability and they could also significantly increase cell proliferation in low glucose. The proliferative effect of insulin and BLX-1002 was also evident at 11 mM of glucose. In addition, insulin, metformin, BLX-1002, pioglitazone, and candesartan significantly decreased the caspase-3 activity and the subsequent DNA fragmentation evoked by palmitate, suggesting a protective effect of the drugs against lipoapoptosis.
Our results suggest that the anti-diabetic and cardioprotective agents mentioned above have direct and beneficial effects on endothelial cell viability, regeneration and apoptosis. This may add yet another valuable property to their therapeutic effect, increasing their clinical utility in type 2 diabetic patients in whom endothelial dysfunction is a prominent feature that adversely affect their survival.
Authors’ original file for figure 112933_2012_458_MOESM1_ESM.ppt
Authors’ original file for figure 212933_2012_458_MOESM2_ESM.ppt
Authors’ original file for figure 312933_2012_458_MOESM3_ESM.ppt
Authors’ original file for figure 412933_2012_458_MOESM4_ESM.ppt
Authors’ original file for figure 512933_2012_458_MOESM5_ESM.ppt
Cifarelli V, Geng X, Styche A, Lakomy R, Trucco M, Luppi P: C-peptide reduces high-glucose-induced apoptosis of endothelial cells and decreases NAD(P)H-oxidase reactive oxygen species generation in human aortic endothelial cells. Diabetologia. 2011, 54 (10): 2702-2712. 10.1007/s00125-011-2251-0. CrossRefPubMed
Smith U: Pioglitazone: mechanism of action. Int J Clin Pract Suppl. 2001, 121: 13-18. PubMed
Matsumoto N, Manabe H, Ochiai J, Fujita N, Takagi T, Uemura M, Naito Y, Yoshida N, Oka S, Yoshikawa T: An AT1-receptor antagonist and an angiotensin-converting enzyme inhibitor protect against hypoxia-induced apoptosis in human aortic endothelial cells through upregulation of endothelial cell nitric oxide synthase activity. Shock. 2003, 19 (6): 547-552. 10.1097/01.shk.0000070734.34700.80. CrossRefPubMed
Brunmair B, Staniek K, Lehner Z, Dey D, Bolten CW, Stadlbauer K, Luger A, Furnsinn C: Lipophilicity as a determinant of thiazolidinedione action in vitro: findings from BLX-1002, a novel compound without affinity to PPARs. Am J Physiol Cell Physiol. 2011, 300 (6): C1386-C1392. 10.1152/ajpcell.00401.2010. CrossRefPubMed
Zhang F, Dey D, Branstrom R, Forsberg L, Lu M, Zhang Q, Sjoholm A: BLX-1002, a novel thiazolidinedione with no PPAR affinity, stimulates AMP-activated protein kinase activity, raises cytosolic Ca2+, and enhances glucose-stimulated insulin secretion in a PI3K-dependent manner. Am J Physiol Cell Physiol. 2009, 296 (2): C346-C354. CrossRefPubMed
Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, Waldhausl W, et al: Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?. Diabetes. 2004, 53 (4): 1052-1059. 10.2337/diabetes.53.4.1052. CrossRefPubMed
Erdogdu O, Nathanson D, Sjoholm A, Nystrom T, Zhang Q: Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol. 2009, 325 (1-2): 26-35. CrossRef
Edwards SJ, Reader KL, Lun S, Western A, Lawrence S, McNatty KP, Juengel JL: The cooperative effect of growth and differentiation factor-9 and bone morphogenetic protein (BMP)-15 on granulosa cell function is modulated primarily through BMP receptor II. Endocrinology. 2008, 149 (3): 1026-1030. CrossRefPubMed
Serizawa K, Yogo K, Aizawa K, Tashiro Y, Ishizuka N: Nicorandil prevents endothelial dysfunction due to antioxidative effects via normalisation of NADPH oxidase and nitric oxide synthase in streptozotocin diabetic rats. Cardiovasc Diabetol. 2011, 10: 105-10.1186/1475-2840-10-105. PubMedCentralCrossRefPubMed
Davis BJ, Xie Z, Viollet B, Zou MH: Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes. 2006, 55 (2): 496-505. 10.2337/diabetes.55.02.06.db05-1064. CrossRefPubMed
Kim JE, Kim YW, Lee IK, Kim JY, Kang YJ, Park SY: AMP-activated protein kinase activation by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) inhibits palmitate-induced endothelial cell apoptosis through reactive oxygen species suppression. J Pharmacol Sci. 2008, 106 (3): 394-403. 10.1254/jphs.FP0071857. CrossRefPubMed
Artwohl M, Holzenbein T, Furnsinn C, Freudenthaler A, Huttary N, Waldhausl WK, Baumgartner-Parzer SM: Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells. Thromb Haemost. 2005, 93 (5): 810-815. PubMed
Chen J, Li D, Zhang X, Mehta JL: Tumor necrosis factor-alpha-induced apoptosis of human coronary artery endothelial cells: modulation by the peroxisome proliferator-activated receptor-gamma ligand pioglitazone. J Cardiovasc Pharmacol Ther. 2004, 9 (1): 35-41. 10.1177/107424840400900i106. CrossRefPubMed
- Effects of some anti-diabetic and cardioprotective agents on proliferation and apoptosis of human coronary artery endothelial cells
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II